Theravance Biopharma
Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases through the discovery, development, and commercialization of medicines that make a difference in patients' and caregivers' lives. The company leverages insight and innovation, collaborates with partners, and is committed to creating value for shareholders. It develops medicines such as YUPELRI® for COPD and investigational programs like ampreloxetine for neurogenic orthostatic hypotension.
Industries
Nr. of Employees
large (251-1000)
Patents
Products
Revefenacin inhalation solution (marketed LAMA for COPD)
A long-acting muscarinic antagonist formulated as an inhalation solution indicated for maintenance treatment in COPD patients.
Ampreloxetine (investigational norepinephrine reuptake inhibitor)
An investigational, once‑daily norepinephrine reuptake inhibitor in clinical development for symptomatic neurogenic orthostatic hypotension, with demonstrated pharmacodynamic effects on blood pressure in clinical studies.
Revefenacin inhalation solution (marketed LAMA for COPD)
A long-acting muscarinic antagonist formulated as an inhalation solution indicated for maintenance treatment in COPD patients.
Ampreloxetine (investigational norepinephrine reuptake inhibitor)
An investigational, once‑daily norepinephrine reuptake inhibitor in clinical development for symptomatic neurogenic orthostatic hypotension, with demonstrated pharmacodynamic effects on blood pressure in clinical studies.
Services
Support for investigator‑initiated clinical research in specified disease areas, including information and operational links for investigators.
Provision and administration of grant funding related to disease research areas (e.g., COPD).
Policy and administrative support for expanded access requests for investigational products.
Selectively partnering programs for co-development and co-commercialization to accelerate development timelines and market access.
Commercial execution for marketed products including sales, marketing strategy and managed markets support.
Support for investigator‑initiated clinical research in specified disease areas, including information and operational links for investigators.
Provision and administration of grant funding related to disease research areas (e.g., COPD).
Policy and administrative support for expanded access requests for investigational products.
Selectively partnering programs for co-development and co-commercialization to accelerate development timelines and market access.
Commercial execution for marketed products including sales, marketing strategy and managed markets support.
Expertise Areas
- Clinical trial management
- Regulatory compliance and submissions (FDA/EMA)
- Respiratory and neurologic drug development
- Clinical pharmacology and pharmacodynamics
Key Technologies
- Randomized withdrawal trial design
- Ambulatory blood pressure monitoring
- Clinical outcome assessment instruments (PROs)
- Pharmacodynamic and biomarker assessments
News & Updates
Studies on ampreloxetine, including its effects on blood pressure and catecholamines in patients with neurogenic orthostatic hypotension.
Evaluation of clinically meaningful changes in the OHSA domain of the OHQ.
A phase 3, 22-week, multi-center, randomized withdrawal study of ampreloxetine in treating symptomatic nOH.
Studies on ampreloxetine, including its effects on blood pressure and catecholamines in patients with neurogenic orthostatic hypotension.
Evaluation of clinically meaningful changes in the OHSA domain of the OHQ.
A phase 3, 22-week, multi-center, randomized withdrawal study of ampreloxetine in treating symptomatic nOH.